Assessment of robustness of institutional applied clinical target volume (CTV) to planning target volume (PTV) margin in cervical cancer using biological models

Abstract

The aim of this study is to investigate the robustness of our institutionally applied clinical target volume (CTV)-to-planning target volume (PTV) margins in cervical cancer patients in terms of an equivalent uniform dose (EUD) based on tumor control probability (TCP). We simulated target motion using 25 IMRT cervical cancer plans to demonstrate the effect of geometrical uncertainties on the EUD and TCP. The different components of the total geometrical uncertainties budget were estimated. The biological effects were compared by calculating the EUDs from the trial DVHs. The impact of geometric uncertainties was calculated as a percentage of the difference between 〖EUD〗_static and 〖EUD〗_motion, where the 〖EUD〗_static is the EUD calculated from the target DVHs and 〖EUD〗_motion is averaged, over a 1000 calculated EUDs for each of the analyzed IMRT treatment plans. The multivariate nonlinear regression was used to find the predicted difference between the static and motion EUD. The estimate of the systematic and random motion errors were Σ_(total(SI,LR,AP)) (mm)=(2.6; 2.5; 1.8) and σ_(total(SI,LR,AP)) (mm)=(3.4; 1.4; 3.4). For average 〈EUD〉_motion=44.3 Gy (over 25 patients) we have found a TCP decrease of about 1%, %(ΔTCP)≈1% for predefined PTV margin. According to the calculated EUD motion-distributions, for particular patients, the CTV does receive the prescribed EUD of 45 Gy. The predicted difference in EUD showed that our isotropic margin of 10 mm is large enough to absorb geometric uncertainties and ensure dose coverage of the moving CTV in the cervical cancer patients.